Clinical Trial Update: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tisotumab vedotin to chemotherapy in recurrent or metastatic cervical cancer has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• TIVDAK (tisotumab vedotin)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Cervical Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-08-09